Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention group: Herbal extract capsule (500 mg) will be administered 2 times a day orally for 3 months. Control group: Metformin capsule (250 mg) mixed with toast powder (250 mg) will be administe
Treatment - Drugs
Sponsors
Vice chancellor for research, Institute of Medicinal Plants
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:Type 2 diabetic patients; aged 40 to 60 years; fasting blood glucose levels from 130 to 160 mg/dL; blood glycosylated hemoglobin levels from 7.5 to 8.5 percent; under oral anti-hyperglycemic drugs therapy taking maximum1000 mg metformin and 10 mg glybencalamid daily. Exclusion criteria: Patients receiving insulin therapy; patients with cardiovascular, renal, hepatic, hematological, hypothyroidism, vertigo and seizure diseases; patients with a history of gallstones or gallbladder surgery; patients under estrogen, steroid, beta-blocker and thiazide therapy; women planning for pregnancy; pregnant women; breast-feeding women.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level will be determined in laboratory by commercial standard kit.;Glycosylated hemoglobin (HbA1c). Timepoint: At starting of the study and after 3 months. Method of measurement: HbA1c percent will be determined in laboratory by commercial standard kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercial standard kit.;Cholesterol. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercial standard kit.;Low-density lipoprotein (LDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood LDL level will be determined in laboratory by commercial standard kit.;High-density lipoprotein (HDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HDL level will be determined in laboratory by commercial standard kit.;Aspartate aminotransferase (AST). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood AST level will be determined in laboratory by commercial standard kit.;Alanine aminotransferase (ALT). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood ALT level will be determined in laboratory by commercial standard kit.;Blood urea nitrogen (BUN). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood BUN level will be determined in laboratory by commercial standard kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercial standard kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHasan Fallah Huseini
Institute of Medicinal Plants
Outcome results
None listed